<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8390">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02115204</url>
  </required_header>
  <id_info>
    <org_study_id>EC-Doc</org_study_id>
    <nct_id>NCT02115204</nct_id>
  </id_info>
  <brief_title>4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF</brief_title>
  <official_title>Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --&gt; 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AGO Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Study Group</source>
  <oversight_info>
    <authority>Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer
      (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West
      German Study Group and &quot;Arbeitsgemeinschaft Gyn√§kologische Onkologie&quot; (WSG-AGO) EC-Doc is a
      large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3
      involved lymph nodes (LN).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparison of event-free survival</measure>
    <time_frame>60 months after end of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of overall survival</measure>
    <time_frame>60 months after end of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of toxicity (measured as number of adverse events)</measure>
    <time_frame>60 months after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of quality of life</measure>
    <time_frame>60 months after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of cost effectiveness across the applied regimens in relation to event-free survival</measure>
    <time_frame>60 months after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2011</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>EC-Doc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v.,  q = 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMF/CEF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>EC-Doc</arm_group_label>
    <arm_group_label>CMF/CEF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>EC-Doc</arm_group_label>
    <arm_group_label>CMF/CEF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>EC-Doc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>CMF/CEF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <arm_group_label>CMF/CEF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients

          -  Age 18-65 years

          -  Eastern Cooperative Oncology Group (ECOG) status &lt; 2

          -  Surgery: R0-resection and &gt;= 10 removed axillary lymph nodes

          -  M0 by chest x-ray, bone scintigraphy and liver sonography

        Exclusion Criteria:

          -  Polyneuropathy

          -  Creatinin (serum) &gt; 1,4 mg/dl; Bilirubin (serum) &gt; 2,0 mg/dl

          -  Cardia dysfunction, ejection fraction &lt; lower normal value of each institution

          -  Hematopoeitic insufficiency: leucocytes &lt; 3,5 G/l, thrombocytes &lt; 100 G/l

          -  second malignant neoplasia, except curatively treated basalioma of the skin

          -  Surgery before more the six weeks (42 days)

          -  Concurrent pregnancy; patients of childbearing potential must implement a highly
             effective (less than 1% failure rate) non-hormonal contraceptive measures during the
             study treatment

          -  Breast feeding woman

          -  Sequential breast cancer

          -  Reasons indicating risk of poor compliance

          -  Patients not able to consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Nitz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ev. Hospital Bethesda, Moenchengladbach</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ev. Hospital Bethesda</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
